{"title":"Association Between Serum Uric Acid and Atrial Fibrillation in Patients With Hypertension: A Systematic Review and Meta-Analysis.","authors":"Nianping Tang, Zhouling Luo, Yao Ye, Gang Wu","doi":"10.31083/RCM28168","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation (AF) and hypertension are associated with inflammatory response and oxidative stress. Uric acid (UA) is the product of the oxidative reaction and a surrogate indicator of oxidative stress. However, whether UA imposes a greater risk of AF in hypertensive patients remains unclear. This study sought to evaluate the evidence supporting an association between serum uric acid (SUA) and AF in patients with hypertension.</p><p><strong>Methods: </strong>The observational studies in which SUA was measured and AF was reported in hypertension were searched for in the PubMed, Cochrane Library, EMBASE, and Web of Science databases until December 31, 2023, without language restrictions. We calculated the pooled mean difference of SUA between those with and without AF in the hypertension patients.</p><p><strong>Results: </strong>A total of 5 studies were included. Three cross-sectional studies comprised 4191 patients with hypertension. The standardized mean difference (SMD) of SUA for those with AF was 0.60 (95% confidence interval (CI) 0.15-1.05) compared with those without AF. Two cohort studies evaluated 9810 individuals with hypertension, and the risk of AF was 0.03 (95% CI -0.05-0.11), which revealed no significant difference between high SUA and normal SUA.</p><p><strong>Conclusion: </strong>Our findings demonstrate a significant association between SUA and AF in patients with hypertension. Further studies are needed to investigate the underlying pathophysiological mechanisms and to assess the value of SUA as a marker or a potential target for the therapy of AF in patients with hypertension.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"26 5","pages":"28168"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135643/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in cardiovascular medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31083/RCM28168","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Atrial fibrillation (AF) and hypertension are associated with inflammatory response and oxidative stress. Uric acid (UA) is the product of the oxidative reaction and a surrogate indicator of oxidative stress. However, whether UA imposes a greater risk of AF in hypertensive patients remains unclear. This study sought to evaluate the evidence supporting an association between serum uric acid (SUA) and AF in patients with hypertension.
Methods: The observational studies in which SUA was measured and AF was reported in hypertension were searched for in the PubMed, Cochrane Library, EMBASE, and Web of Science databases until December 31, 2023, without language restrictions. We calculated the pooled mean difference of SUA between those with and without AF in the hypertension patients.
Results: A total of 5 studies were included. Three cross-sectional studies comprised 4191 patients with hypertension. The standardized mean difference (SMD) of SUA for those with AF was 0.60 (95% confidence interval (CI) 0.15-1.05) compared with those without AF. Two cohort studies evaluated 9810 individuals with hypertension, and the risk of AF was 0.03 (95% CI -0.05-0.11), which revealed no significant difference between high SUA and normal SUA.
Conclusion: Our findings demonstrate a significant association between SUA and AF in patients with hypertension. Further studies are needed to investigate the underlying pathophysiological mechanisms and to assess the value of SUA as a marker or a potential target for the therapy of AF in patients with hypertension.
背景：心房颤动（AF）和高血压与炎症反应和氧化应激有关。尿酸（UA）是氧化反应的产物，是氧化应激的替代指标。然而，UA是否会增加高血压患者发生房颤的风险尚不清楚。本研究旨在评估高血压患者血清尿酸（SUA）与房颤之间的关联。方法：在PubMed、Cochrane图书馆、EMBASE和Web of Science数据库中检索截至2023年12月31日的高血压患者中测量SUA和报告AF的观察性研究，无语言限制。我们计算合并和不合并房颤的高血压患者SUA的汇总平均差异。结果：共纳入5项研究。三项横断面研究包括4191例高血压患者。与无房颤者相比，房颤患者SUA的标准化平均差（SMD）为0.60（95%可信区间（CI） 0.15-1.05）。两项队列研究评估了9810例高血压患者，房颤的风险为0.03 (95% CI -0.05-0.11)，显示高SUA与正常SUA之间无显著差异。结论：我们的研究结果表明高血压患者的SUA和房颤之间存在显著的关联。需要进一步的研究来调查潜在的病理生理机制，并评估SUA作为高血压患者房颤治疗的标志物或潜在靶点的价值。
期刊介绍：
RCM is an international, peer-reviewed, open access journal. RCM publishes research articles, review papers and short communications on cardiovascular medicine as well as research on cardiovascular disease. We aim to provide a forum for publishing papers which explore the pathogenesis and promote the progression of cardiac and vascular diseases. We also seek to establish an interdisciplinary platform, focusing on translational issues, to facilitate the advancement of research, clinical treatment and diagnostic procedures. Heart surgery, cardiovascular imaging, risk factors and various clinical cardiac & vascular research will be considered.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
